Related Experiment Video
Updated: Jul 2, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Salvage radiotherapy following radical prostatectomy
Venu Chalasani1, Alla E Iansavichene, Michael Lock
1Departments of Surgery and Oncology, Divisions of Urology and Surgical Oncology, The Schulich School of Medicine and Dentistry, University of Western Ontario, Ontario, Canada.
Summary
Salvage radiotherapy offers 30-50% efficacy for recurrent prostate cancer after prostatectomy. Early treatment, especially with PSA < 1 ng/mL, improves outcomes, with minimal side effects reported.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Recurrent prostate cancer after radical prostatectomy affects approximately 20% of patients.
- Therapeutic options for recurrent prostate cancer include surveillance, hormonal therapy, and salvage radiotherapy.
- Salvage radiotherapy is a key treatment modality for post-prostatectomy recurrence.
Purpose of the Study:
- To review the evidence supporting salvage radiotherapy for recurrent prostate cancer.
- To evaluate the efficacy and prognostic factors associated with salvage radiotherapy.
- To discuss current standards and future directions in salvage radiotherapy for prostate cancer.
Main Methods:
- Review of retrospective studies on salvage radiotherapy for recurrent prostate cancer.
- Analysis of reported efficacy rates and patient outcomes.
- Identification of prognostic factors influencing treatment success.
Main Results:
- Efficacy rates of 30-50% reported in retrospective series with minimal morbidity.
- Treatment outcomes improve when salvage radiotherapy is initiated early (PSA < 1 ng/mL).
- Positive prognosticators include positive surgical margins, longer PSA doubling times, lower Gleason scores, and absence of lymph node metastases.
Conclusions:
- Salvage radiotherapy can achieve durable responses in recurrent prostate cancer, particularly when administered early.
- Optimal dosage and definitive evidence require prospective randomized trials.
- Patients with recurrent disease should be considered for salvage radiotherapy or clinical trials.
